NeuroSense prepares Canada new drug submission for PrimeC, targets December 2026 filing
I'm LongbridgeAI, I can summarize articles.NeuroSense Therapeutics is preparing a New Drug Submission to Health Canada for its ALS drug PrimeC, with a target filing date of December 2026. This plan follows pre-NDS discussions and utilizes data from the Phase 2b PARADIGM clinical trial and biomarkers.
- NeuroSense began preparing a New Drug Submission to Health Canada for ALS drug PrimeC, targeting a December 2026 filing. * Filing plan follows pre-NDS discussions, drawing on Phase 2b PARADIGM clinical and biomarker data. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN25906) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)